STOCK TITAN

Procaps Group Sa Stock Price, News & Analysis

PROC Nasdaq

Welcome to our dedicated page for Procaps Group Sa news (Ticker: PROC), a resource for investors and traders seeking the latest updates and insights on Procaps Group Sa stock.

Procaps Group, S.A. (PROC) is frequently in the news as an integrated Latin American healthcare and pharmaceutical services company active in medicinal and botanical manufacturing. Company announcements emphasize its role in developing, manufacturing, and marketing over-the-counter (OTC) pharmaceutical products, prescription pharmaceutical drugs (Rx), nutritional supplements, high-potency clinical solutions, and hospital supplies that reach more than 50 countries.

The PROC news feed on Stock Titan aggregates these public communications so readers can follow how Procaps addresses governance, financial reporting, and operational topics. Recent releases have covered the company’s internal investigation into historical accounting matters, delays in filing its Form 20-F, and plans to restate certain historical financial statements. News has also highlighted remediation plans to strengthen internal controls and SOX compliance, along with changes to board composition, committee structures, and executive leadership roles.

Investors and observers can use this page to review Procaps’ updates on financial restructuring efforts, including forbearance agreements with lenders, a secured convertible note subscription agreement, and other steps the company describes as supporting liquidity and long-term sustainability. Regulatory and listing developments are another key theme, with disclosures about Nasdaq notices regarding filing delinquencies, hearing requests, and Nasdaq’s determination to delist the company’s ordinary shares, alongside the company’s statement that trading is expected to transition to the OTC Expert Market.

By consolidating these releases, the PROC news page provides a single place to read about Procaps’ pharmaceutical and nutraceutical activities, governance initiatives, and restructuring plans as described by the company in its own announcements.

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.28%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.84%
Tags
management
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.22%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
conferences
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.39%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
conferences earnings
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.48%
Tags
none

FAQ

What is the current stock price of Procaps Group Sa (PROC)?

The current stock price of Procaps Group Sa (PROC) is $1.01 as of February 7, 2025.

What is the market cap of Procaps Group Sa (PROC)?

The market cap of Procaps Group Sa (PROC) is approximately 114.0M.

PROC Rankings

PROC Stock Data

113.95M
19.15M
Medicinal and Botanical Manufacturing
Manufacturing
Link
LU
Luxembourg City

PROC RSS Feed